1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Oral Cancer – Pipeline Review, H1 2013

Oral Cancer – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Oral Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Oral Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Oral Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cancer. Oral Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oral Cancer.
- A review of the Oral Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oral Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Oral Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oral Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Oral Cancer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Oral Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Oral Cancer 7
Oral Cancer Therapeutics under Development by Companies 9
Oral Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Oral Cancer Therapeutics - Products under Development by Companies 15
Oral Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Oral Cancer Therapeutics Development 17
NexMed, Inc. 17
Oral Cancer - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
HPPH - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Survivin-Derived Peptide Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Taxotere + Cisplatin + 5-FU - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
vesnarinone - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
curcumin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
paclitaxel - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
celecoxib - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
interleukin-15 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Oral Cancer Therapeutics - Drug Profile Updates 36
Oral Cancer Therapeutics - Discontinued Products 37
Oral Cancer Therapeutics - Dormant Products 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

Number of Products Under Development for Oral Cancer, H1 2013 7
Products under Development for Oral Cancer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
NexMed, Inc., H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Oral Cancer Therapeutics - Drug Profile Updates 36
Oral Cancer Therapeutics - Discontinued Products 37
Oral Cancer Therapeutics - Dormant Products 38



List of Figures

Number of Products under Development for Oral Cancer, H1 2013 7
Products under Development for Oral Cancer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.